

Yersinia enterocolitica

Disease Agent:

- *Yersinia enterocolitica*

Disease Agent Characteristics:

- Gram-negative, facultatively anaerobic, bacillus to coccobacillus, nonmotile, nonspore-forming, facultatively intracellular bacterium
- Order: Enterobacteriales; Family: Enterobacteriaceae
- Size: 0.5-0.8 × 1.0-2.0 μm
- Nucleic acid: The genome of *Yersinia enterocolitica* is 4616 kb of DNA.
- Growth of *Y. enterocolitica* is enhanced by cold enrichment and exposure to 4°C for a period of time, and the organism is capable of growth at 4°C.

Disease Name:

- Yersiniosis

Priority Level:

- Scientific/Epidemiologic evidence regarding blood safety: Low/Moderate; decreased frequency of transfusion-associated cases over the past 10 years
- Public perception and/or regulatory concern regarding blood safety: Very low
- Public concern regarding disease agent: Absent

Background:

- *Y. enterocolitica* is identified throughout the world, and is isolated from multiple environmental sources, including water, contaminated foods, and a wide range of wild and domestic animals. Foodborne outbreaks are recognized.
- It is an infrequently recognized cause of diarrhea and abdominal pain in the US but is relatively more commonly identified in northern Europe. Infections have been documented in other parts of the world, including South America, Africa, and Asia, but *Y. enterocolitica* is not considered an important cause of tropical diarrhea.
- *Y. enterocolitica* is highly heterogeneous and can be divided into several bioserotypes, only a few of which are known to be associated with human disease. Most *Y. enterocolitica* strains causing human yersiniosis belong to bioserotypes 1B/O:8, 2/O:5,27, 2/O:9, 3/O:3, and 4/O:3.
- Inefficient isolation methods have compromised accurate estimation of the prevalence of *Y. enterocolitica* disease.

Common Human Exposure Routes:

- Ingestion of contaminated foods (plants or animal origin)

- Direct contact with animal sources, particularly pigs

Likelihood of Secondary Transmission:

- Person-to-person transmission is rare. However, contamination of food by an infected food handler and nosocomial infections have been described.

At-Risk Populations:

- Infants and children have the highest risk of symptomatic infection.
- Individuals with advanced liver disease and syndromes associated with iron overload have the highest risk of septicemic disease.
- Rural populations and those living in cooler temperate zones
- Certain racial and ethnic groups through exposure to particular foods and food preparation methods

Vector and Reservoir Involved:

- Domestic animals (livestock) are the important animal reservoir. The major animal reservoir for strains that cause human illness is pigs.

Blood Phase:

- Prolonged or recurrent bacteremia occurs in some individuals after acute or chronic symptomatic or subclinical infection.
- Persistent infection, when present, lasts for weeks in most instances, but it can persist for several years.

Survival/Persistence in Blood Products:

- Full shelf life and beyond for whole blood and RBCs
- Although significant bacterial growth increases over time, sepsis has been described with RBCs stored for as short a period as 14 days.
- Bacteria can survive in phagocytic cells and extracellularly.
- Plasma depletion typical of RBC units reduces or prevents complement-mediated killing of serum sensitive *Y. enterocolitica*.
- Time-dependent lysis of white blood cells releases additional organisms and senescence of RBCs releases iron that stimulates and supports growth.
- Variability in growth and survival in blood products among serotypes may be related to serum resistance at storage temperatures and their capacity to bind iron.

Transmission by Blood Transfusion:

- Multiple case reports (>30) of transfusion-transmission of *Y. enterocolitica* from asymptomatic donors have occurred since 1975 (lack of reports prior to that may have been a result of shorter storage times in use), including from autologous transfusion. *Y. enterocolitica* accounts for more than half the cases of

sepsis arising from transfusion of RBCs. At least one case of a transfusion reaction due to *Y. enterocolitica* contaminating a pooled platelet concentrate has been reported.

- Clinical disease symptoms in transfusion recipients may be a result of endotoxemia and/or subsequent growth of the organism.

Cases/Frequency in Population:

- Estimated incidence in the US for 2003 was 0.4 per 100,000, with highest rates among infants and young children. These incidence rates are for symptomatic disease accompanied by positive stool culture.
- Incidence of subclinical and asymptomatic infections is unknown.
- Transfusion-transmitted *Y. enterocolitica* infection may be decreasing in recent years possibly because of interventions, such as leukoreduction, or because incidence of infection in the community is decreasing.

Incubation Period:

- Food-borne gastroenteritis, typically 2-5 days
- In most cases of transfusion-associated yersiniosis, fever and hypotension occurred 1-2 hours after the start of transfusion of contaminated blood.

Likelihood of Clinical Disease:

- Rate of asymptomatic gastrointestinal infection is unknown.
- High in blood recipients who received a transfusion with a unit containing *Y. enterocolitica*

Primary Disease Symptoms:

- Enterocolitis accounts for two-thirds of reported cases of symptomatic *Y. enterocolitica* infections. This is characterized by fever, diarrhea, nausea, vomiting, and abdominal pain lasting 1-3 weeks. Patients with mesenteric adenitis and/or terminal ileitis have fever, right lower quadrant pain and tenderness, and leukocytosis, and as many as 10% may undergo operation for suspected appendicitis.
- A reactive polyarthritis, lasting less than a year in general has been specifically related to the presence of HLA-B27 in individuals with yersiniosis. Ankylosing spondylitis rarely develops. Reiter's syndrome (arthritis, urethritis, and conjunctivitis) also has been reported and is associated with HLA-B27 antigen.
- Exudative pharyngitis is seen with *Y. enterocolitica* infections. In one enteritis outbreak in the US, 8% of patients presented with acute pharyngitis and fever, without accompanying diarrhea.
- *Y. enterocolitica* septicemia is uncommon but severe and often fatal. It is most often reported in patients with underlying immunocompromising conditions,

the elderly, and patients with iron overload. Septicemic patients may develop metastatic abscesses, endocarditis, and mycotic aneurysms.

Severity of Clinical Disease:

- Primary septicemic transfusion-related *Y. enterocolitica* infection is a severe disease.

Mortality:

- Death is uncommon with naturally acquired infection.
- High for *Y. enterocolitica* bacteremia related to transfusion; approximately 50% mortality rate

Chronic Carriage:

- Metastatic infections after bacteremia can cause subacute and chronic infections, especially among high-risk individuals.
- Chronic infection after acute gastrointestinal infection has been alleged on the basis of persisting gastrointestinal signs and symptoms, persistently positive serologies, and the development of rheumatic syndromes. Microbiologic documentation that viable organisms persist in these patients is generally not provided.

Treatment Available/Efficacious:

- Susceptible to a variety of antimicrobial agents including aminoglycosides, fluoroquinolones, chloramphenicol, tetracyclines, and trimethoprim-sulfamethoxazole

Agent-Specific Screening Question(s):

- No specific question is in use.
- Not indicated because of the low incidence of transfusion-associated *Yersinia* sepsis
- Questions about recent gastrointestinal illness have been documented to lack sensitivity and specificity.

Laboratory Test(s) Available:

- No FDA-licensed blood donor screening test exists.
- Options for serologic tests include EIAs that screen for antibody, especially IgM, directed to virulence plasmid-mediated outer proteins.
- Direct detection: *Yersinia* species grow well on media that support the growth of Enterobacteriaceae.
- Culture of whole blood and RBCs for *Y. enterocolitica* may be negative despite spiking of the blood with viable organisms. Intracellular sequestration has been hypothesized to account for such negative cultures.
- Other techniques that have been used include IFA, electrochemiluminescence, and NAT-based detection methods.

Currently Recommended Donor Deferral Period:

- No FDA Guidance or AABB Standard exists.
- The length of a deferral period for a donor with diagnosed and resolved *Y. enterocolitica* gastroenteritis is unclear. In the absence of any chronic disease manifestations, it may be acceptable to consider such a donor as eligible when fully recovered, either spontaneously or after treatment.

Impact on Blood Availability:

- Agent-specific screening question(s): Not applicable
- Laboratory test(s) available: Not applicable

Impact on Blood Safety:

- Agent-specific screening question(s): Not applicable
- Laboratory test(s) available: Not applicable

Leukoreduction Efficacy:

- The effectiveness of leukoreduction in reducing transmission and clinical cases of *Y. enterocolitica* is unknown.
- In laboratory studies, leukocyte reduction filtration can reduce *Y. enterocolitica* contamination by removing bacteria-laden phagocytic cells. Prefiltration storage at room temperature allows for free organisms to be phagocytized by WBCs prior to filtration.

Pathogen Reduction Efficacy for Plasma Derivatives:

- Specific data indicate that the multiple steps in the fractionation process are robust and capable of inactivating and/or removing bacteria at concentrations that may be present in plasma.

Other Prevention Measures:

- Visual examination of units of blood looking for gross contamination is unlikely to be sensitive.
- Testing of RBC units of 25 days or older for endotoxin or screening for bacteria by stained smear has been proposed, but rapid and reliable tests are not available.

- Discarding units of 25 days or older has also been suggested, but this would result in significant reduction in supply of RBCs for transfusion.
- Storage of RBCs at 0°C has been proposed as a way to delay and reduce growth of *Y. enterocolitica*.

Suggested Reading:

1. Allain JP, Bianco C, Blajchman MA, Brecher ME, Busch M, Leiby D, Lin L, Stramer S. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. *Transfus Med Rev* 2005;19:110-26.
2. Arduino MJ, Bland LA, Tipple MA, Aguerro SM, Favero MS, Jarvis WR. Growth and endotoxin production of *Yersinia enterocolitica* and *Enterobacter agglomerans* in packed erythrocytes. *J Clin Microbiol* 1989;27:1483-5.
3. Bradley RM, Gander RM, Patel SK, Kaplan HS. Inhibitory effect of 0°C storage on the proliferation of *Yersinia enterocolitica* in donated blood. *Transfusion* 1997;37:691-5.
4. Feng P, Keasler SP, Hill WE. Direct identification of *Yersinia enterocolitica* in blood by polymerase chain reaction amplification. *Transfusion* 1992;32:850-4.
5. Gibb AP, Martin KM, Davidson GA, Walker B, Murphy WG. Modeling the growth of *Yersinia enterocolitica* in donated blood. *Transfusion* 1994;34:304-10.
6. Grossman BJ, Kollins P, Lau PM, Perreten JL, Bowman RJ, Malcolm S, Palko WM. Screening blood donors for gastrointestinal illness: a strategy to eliminate carriers of *Yersinia enterocolitica*. *Transfusion* 1991;31:500-1.
7. Hogman CF, Engstrand L. Factors affecting growth of *Yersinia enterocolitica* in cellular blood products. *Transfus Med Rev* 1996;10:259-75.
8. Kuehnert MJ, Jarvis WR, Schaffer DA, Chaffin DJ. Platelet transfusion reaction due to *Yersinia enterocolitica*. *JAMA* 1997;278:550.
9. Kuehnert MJ, Roth VR, Haley NR, Gregory KR, Elder KV, Schreiber GB, Arduino MJ, Holt SC, Carson LA, Banerjee SN, Jarvis WR. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. *Transfusion* 2001;41:1493-9.